Literature DB >> 24022147

At the frontiers of lung fibrosis therapy.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24022147     DOI： 10.1038/nbt.2687

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

2.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Authors:  Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2011-05-13       Impact factor: 79.321

3.  Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.

Authors:  Vivian Barry-Hamilton; Rhyannon Spangler; Derek Marshall; Scott McCauley; Hector M Rodriguez; Miho Oyasu; Amanda Mikels; Maria Vaysberg; Haben Ghermazien; Carol Wai; Carlos A Garcia; Arleene C Velayo; Brett Jorgensen; Donna Biermann; Daniel Tsai; Jennifer Green; Shelly Zaffryar-Eilot; Alison Holzer; Scott Ogg; Dung Thai; Gera Neufeld; Peter Van Vlasselaer; Victoria Smith
Journal:  Nat Med       Date:  2010-09-05       Impact factor: 53.440

4.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin J Anstrom; Talmadge E King; Joseph A Lasky; Fernando J Martinez
Journal:  N Engl J Med       Date:  2012-05-20       Impact factor: 91.245

5.  Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Ulrich Costabel; Moises Selman; Dong Soon Kim; David M Hansell; Andrew G Nicholson; Kevin K Brown; Kevin R Flaherty; Paul W Noble; Ganesh Raghu; Michèle Brun; Abhya Gupta; Nolwenn Juhel; Matthias Klüglich; Roland M du Bois
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

6.  The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak.

Authors:  Andrew M Tager; Peter LaCamera; Barry S Shea; Gabriele S Campanella; Moisés Selman; Zhenwen Zhao; Vasiliy Polosukhin; John Wain; Banu A Karimi-Shah; Nancy D Kim; William K Hart; Annie Pardo; Timothy S Blackwell; Yan Xu; Jerold Chun; Andrew D Luster
Journal:  Nat Med       Date:  2007-12-09       Impact factor: 53.440

Review 7.  PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery.

Authors:  Toby M Maher
Journal:  Eur Respir Rev       Date:  2013-06-01
  7 in total
  4 in total

1.  Landmark approvals in idiopathic pulmonary fibrosis.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2014-11       Impact factor: 54.908

Review 2.  The multifaceted roles of FOXM1 in pulmonary disease.

Authors:  Yumei Li; Feng Wu; Qi Tan; Mengfei Guo; Pei Ma; Xuan Wang; Shuai Zhang; Juanjuan Xu; Ping Luo; Yang Jin
Journal:  Cell Commun Signal       Date:  2019-04-16       Impact factor: 5.712

3.  Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases.

Authors:  Xiaohe Li; Yinshan Fang; Dingyuan Jiang; Yingying Dong; Yingying Liu; Si Zhang; Jiasen Guo; Chao Qi; Chenjing Zhao; Fangxin Jiang; Yueyue Jin; Jing Geng; Cheng Yang; Hongkai Zhang; Bin Wei; Jiurong Liang; Chen Wang; Huaping Dai; Honggang Zhou; Dianhua Jiang; Wen Ning
Journal:  Mol Ther       Date:  2020-09-23       Impact factor: 11.454

4.  IL-32γ attenuates airway fibrosis by modulating the integrin-FAK signaling pathway in fibroblasts.

Authors:  Gyong Hwa Hong; So-Young Park; Hyouk-Soo Kwon; Bo-Ram Bang; Jaechun Lee; Sang-Yeob Kim; Chan-Gi Pack; Soohyun Kim; Keun-Ai Moon; Tae-Bum Kim; Hee-Bom Moon; You Sook Cho
Journal:  Respir Res       Date:  2018-09-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.